{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:57:04Z","timestamp":1761897424560,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalimaging.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Imaging"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clinimag.2020.10.052","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T17:29:34Z","timestamp":1604597374000},"page":"29-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study"],"prefix":"10.1016","volume":"71","author":[{"given":"Jill","family":"Gluskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Plodkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Girshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Sarasohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa","family":"Viteri-Jusu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumar","family":"Hayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clinimag.2020.10.052_bb0005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2011.04.008","article-title":"mTOR inhibitors in advanced renal cell carcinoma","volume":"25","author":"Voss","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.clinimag.2020.10.052_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9110152","article-title":"Evolving significance and future relevance of anti-angiogenic activity of mTOR inhibitors in cancer therapy","volume":"9","author":"Faes","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.clinimag.2020.10.052_bb0015","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9207.1","article-title":"mTOR inhibitors in cancer therapy","volume":"5","author":"Xie","year":"2016","journal-title":"F1000Research"},{"issue":"3","key":"10.1016\/j.clinimag.2020.10.052_bb0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hoc.2012.02.014","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer therapy","volume":"26","author":"Gomez-Pinillos","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.clinimag.2020.10.052_bb0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ctrv.2013.08.004","article-title":"Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer","volume":"40","author":"Peddi","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.clinimag.2020.10.052_bb0030","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","volume":"42","author":"Duran","year":"2006","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"issue":"11","key":"10.1016\/j.clinimag.2020.10.052_bb0035","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/JTO.0b013e3181ba20b1","article-title":"Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001)","volume":"4","author":"White","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.clinimag.2020.10.052_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"10.1016\/j.clinimag.2020.10.052_bb0045","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2010.29.2235","article-title":"Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus","volume":"29","author":"Maroto","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clinimag.2020.10.052_bb0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bju.12420","article-title":"Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes","volume":"113","author":"Atkinson","year":"2014","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.clinimag.2020.10.052_bb0055","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10147-014-0764-5","article-title":"Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma","volume":"20","author":"Nozawa","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clinimag.2020.10.052_bb0060","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/ijc.29887","article-title":"mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm","volume":"138","author":"Willemsen","year":"2016","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.clinimag.2020.10.052_bb0065","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.transproceed.2017.12.003","article-title":"Life-threatening everolimus-associated pneumonitis: a case report and a review of the literature","volume":"50","author":"Almeida","year":"2018","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.clinimag.2020.10.052_bb0070","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2017-0343","article-title":"Emerging perspectives on mTOR inhibitor-associated pneumonitis in breast cancer","volume":"23","author":"Alvarez","year":"2018","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.clinimag.2020.10.052_bb0075","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinimag.2020.10.052_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejca.2015.10.015","article-title":"Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach","volume":"53","author":"Nishino","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["Clinical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707120304307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707120304307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:42:41Z","timestamp":1760269361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899707120304307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":16,"alternative-id":["S0899707120304307"],"URL":"https:\/\/doi.org\/10.1016\/j.clinimag.2020.10.052","relation":{},"ISSN":["0899-7071"],"issn-type":[{"type":"print","value":"0899-7071"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"Clinical Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinimag.2020.10.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}